Riskpilot← Back to searchSign inGet full accessPharmacepticum AB
ABActiveOrg 5568927965Economic activity was not specified by tax authority · NACE 0000Est. 20120 employees
Revenue 2024
SEK 0
EBITDA margin
—
-71% vs 2023
Equity ratio
1.8%
Financial strength
Net profit 2024
SEK -2,1M
-18942% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -19K | -71% |
| Net profit | SEK -2,1M | -18942% |
| Total assets | SEK 72,6M | +0% |
| Equity | SEK 1,3M | -61% |
| Employees | 0 | — |
Legal name
Pharmacepticum AB
Org number
5568927965
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
9 maj 2012
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Oulebsir, Faouzia Åberg, Per Vilner Steffan
Company purpose
Bolaget ska bedriva farmacevtisk konsultverksamhet, äga och förvalta fastigheter samt bedriva handel med värdepapper och därmed förenlig verksamhet.
Address
Email
svepaper@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −14 | −25 | −24 | −11 | −19 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | −14 | −25 | −24 | −11 | −19 |
| Net financials | — | — | — | — | −2 076 |
| Profit before tax | −14 | −25 | −24 | −11 | −2 095 |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | −14 | −25 | −24 | −11 | −2 095 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 72 627 | 72 632 | 72 623 | 72 627 | 72 625 |
| Equity | 3 496 | 3 471 | 3 447 | 3 436 | 1 341 |
| Long-term debt | 69 116 | 69 136 | 69 161 | 69 176 | 71 269 |
| Short-term debt | 15 | 24 | 15 | 15 | 15 |
| Total debt | 69 131 | 69 160 | 69 176 | 69 191 | 71 284 |
EBITDA margin
-1882500.0%
This company
15.8%
Market median
-11914657% vs market
20202024
Equity ratio
1.8%
This company
38.2%
Market median
-95% vs market
20202024
Return on equity
-156.2%
This company
18.4%
Market median
-949% vs market
20202024
Net profit margin
-209461900.0%
This company
8.1%
Market median
-2585949483% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
53.15×
This company
0.62×
Market median
-8473% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BN | Audit | 2024 |
FO Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
RA | Audit | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharmacepticum AB 
Gardet AktiebolagBoard members of Pharmacepticum AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Niklas Schierenbeck | Audit | 0 companies |
| Robert Allan Elvir Dohrman | Audit | 0 companies |
| Faouzia Oulebsir | Chief Executive Officer | 0 companies |
| Per Vilner Steffan Åberg | Chairman | 0 companies |
| Katja Sofie Åberg | Board of Directors | 0 companies |
| Camilla Åberg Linder | Board of Directors | 0 companies |
| Vilner Karim Åberg | Board of Directors | 0 companies |